Compare AIRG & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | PYPD |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 71.7M |
| IPO Year | 2016 | 2014 |
| Metric | AIRG | PYPD |
|---|---|---|
| Price | $5.22 | $4.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.25 | ★ $12.25 |
| AVG Volume (30 Days) | 68.6K | ★ 157.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $3.06 |
| 52 Week High | $7.66 | $5.73 |
| Indicator | AIRG | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 35.80 | 57.76 |
| Support Level | $5.17 | $4.15 |
| Resistance Level | $5.66 | $5.07 |
| Average True Range (ATR) | 0.27 | 0.25 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 9.20 | 80.45 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.